Hepatocyte growth factor: A possible mediator of heparin-induced osteoporosis? [1]

Clinical and Applied Thrombosis/Hemostasis

Volumn 9, Issue 2, 2003, Pages 171-172

  Borawski, Jacek ^a   Naumnik, Beata ^a   Myśliwiec, Michał ^a  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; ENOXAPARIN; HEPARIN DERIVATIVE; LOW MOLECULAR WEIGHT HEPARIN; PROTEOHEPARAN SULFATE; RECEPTOR; SCATTER FACTOR;

ANTICOAGULATION; DRUG POTENCY; HEMODIALYSIS; HUMAN; KIDNEY FAILURE; LETTER; OSTEOPENIA; OSTEOPOROSIS; PRIORITY JOURNAL;

EID: 0037709949     PISSN: 10760296     EISSN: None     Source Type: Journal    
DOI: 10.1177/107602960300900214     Document Type: Letter

References (15)

1. Kock HJ, Handschin AE. Osteoblast growth inhibition by unfractionated heparin and by low molecular weight heparins: an in-vitro investigation. Clin Appl Thromb Hemost 2002;8:251.
2. Zarnegar R, Michalopoulos GK. The many faces of hepatocyte growth factor: From hepatopoiesis to hematopoiesis. J Cell Biol 1995;129:1177.
3. Grano M, Galimi F, Zambonin G, et al. Hepatocyte growth factor is a coupling factor for osteoclasts and osteoblasts in vitro. Proc Natl Acad Sci USA 1993;93:7644.
4. Sato T, Hakeda Y, Yamaguchi Y, et al. Hepatocyte growth factor is involved in formation of osteoclasts-like cells mediated by clonal stromal cells (MC3T3-G2/PA6). J Cell Physiol 1995;164:197.
5. Fuller K, Chambers TJ, Gallagher AC. Heparin augments osteoclasts resorption-stimulating activity in serum. J Cell Physiol 1991;147:208.
6. Fuller K, Owens J, Chambers TJ. The effect of hepatocyte growth factor on the behaviour of osteoclasts. Biochem Biophys Res Commun 1995;212:334.
7. Matsumori A, Ono K, Okada M, et al. Immediate increase in circulating hepatocyte growth factor/scatter factor by heparin. J Mol Cell Cardiol 1998;30:2145.
8. Okada M, Matsumori A, Ono K, et al. Hepatocyte growth factor is a major mediator in heparin-induced angiogenesis. Biochem Biophys Res Commun 1999;255:80.
9. Salbach PB, Brückmann M, Turovets O, et al. Heparin-mediated selective release of hepatocyte growth factor in humans. Br J Clin Pharmacol 2000;50:221.
10. Seidel C, Hjorth-Hansen H, Bendz B, et al. Hepatocyte growth factor in serum after injection of unfractionated and low molecular weight heparin in healthy individuals. Br J Haematol 1999;105:641.
11. Taal MW, Masud T, Green D, et al. Risk factors for reduced bone density in haemodialysis patients. Nephrol Dial Transplant 1999;14:1922.
12. Gupta A, Kallenbach LR, Divine GW. Increased risk of hip fractures in U.S. Medicare end-stage renal disease patients. J Bone Miner Res 1997;12(suppl 1):274.
13. Lai KN, Ho K, Cheung RC, Lit LC, et al. Effect of low molecular weight heparin on bone metabolism and hyperlipidemia in patients on maintenance hemodialysis. Int J Artif Organs 2001;24:447.
14. Borawski J, Myśliwiec M. Serum hepatocyte growth factor is associated with viral hepatitis, cardiovascular disease, erythropoietin treatment, and type of heparin in haemodialysis patients. Nephrol Dial Transplant 2002;17:637.
15. Borawski J, Pawlak K, Naumnik B, et al. Relations between oxidative stress, hepatocyte growth factor, and liver disease in hemodialysis patients. Renal Failure (in press).